Lonza appoints Samanta Cimitan as chief commercial officer as WuXi Biologics posts revenue surge
Lonza said it will create a new chief commercial officer position and has selected Samanta Cimitan, the current chief executive of Celonic, to take the role on Jan. 1 next year.
Cimitan will be responsible for managing Lonza's commercial accounts and accelerating growth across its contract development and manufacturing services.
WuXi Biologics reported a notable rise in revenue for the most recent quarter, highlighting continued demand for its biologics manufacturing platform.
The revenue increase and Lonza's leadership appointment both point to a strengthening of the contract manufacturing sector as companies seek external partners for drug development.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “RayzeBio's $173M radiopharma plan; Lonza creates commercial chief position”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that